min read

AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets

AxoSim has entered a definitive agreement to acquire Vyant Bio's StemoniX microBrain™ platform, uniting top-tier organoid technologies to accelerate neurological drug discovery.

12/10/25

min read

AxoSim Appoints Two Biotech Industry Veterans as Co-Chairs of Its Board of Directors

Serial Entrepreneurs Dale Pfost and David Weiner Bring Broad Expertise as AxoSim Expands Its Leadership in Human Organoid Technologies Designed to Make Neurological R&D Faster, More Efficient and More Successful.

12/10/25

min read

AxoSim Appoints Stuart Gibb as VP of Sales and Marketing to Drive Revenue Growth

AxoSim has appointed Stuart Gibb as VP of Sales and Marketing. With over 20 years of experience, Stuart will help accelerate AxoSim's commercial growth in drug discovery and development.

More News

Case Study

Takeda Implements CNS-3D Organoids for Preclinical Neurotoxicity Assessment

CNS-3D organoids provide a human-relevant context for the detection of compound-induced neurotoxicity, supports multiplexed endpoint analysis, and reduces reliance on animal testing.

Spotlight

min read

Organoid Neurotoxicity Testing Embraced by FDA and NIH

Scientists and regulators have long acknowledged the weaknesses in traditional methods used to identify drugs that may harm the central nervous system.

Spotlight

min read

Modeling Myelination and Therapeutic Response in Demyelinating Disorders

CNS-3D and PNS-3D organoids support authentic myelin formation and enable high-throughput measurement of myelination for therapeutic screening.

Spotlight

min read

Organoid Intelligence Offers New Evidence of Learning-related Activity in Human Neural Tissue

Human-derived neural networks can exhibit measurable markers of learning and memory processes.

Case Study

min read

Takeda Implements CNS-3D Organoids for Preclinical Neurotoxicity Assessment

CNS-3D organoids provide a human-relevant context for the detection of compound-induced neurotoxicity, supports multiplexed endpoint analysis, and reduces reliance on animal testing.

Takeda’s Validated Method for CNS Safety

Learn how CNS-3D brain organoids deliver 7.4× better clinical predictivity than animal models in this on-demand webinar with Takeda’s Investigative Toxicology team.

Learn More

Modeling Myelination and Therapeutic Response in Demyelinating Disorders

In the News

Takeda Implements CNS-3D Organoids for Preclinical Neurotoxicity Assessment

CNS-3D organoids provide a human-relevant context for the detection of compound-induced neurotoxicity, supports multiplexed endpoint analysis, and reduces reliance on animal testing.

Spotlights

Subscribe to 28bioNEWS

Organoid Intelligence Offers New Evidence of Learning-related Activity in Human Neural Tissue

Human-derived neural networks can exhibit measurable markers of learning and memory processes.

Case Studies

Takeda’s Validated Method for CNS Safety